Showing results (51-60 of 169) with videos related to

Sort By:
Pageof 17
Lung Cancer (Amsterdam, Netherlands)|June 4, 2014
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancerJoachim von Pawel, Vera Gorbounova, Martin Reck, et al.
Bulletin Du Cancer|May 9, 2016
[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer]Mathilde Cabart, Jean-Sébastien Frénel, Loïc Campion, et al.
Clinical Colorectal Cancer|June 4, 2016
Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter StudyMathilde Cabart, Jean-Sébastien Frénel, Loïc Campion, et al.
Clinical Lung Cancer|December 10, 2023
A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) PatientsMarie Porte, Adrien Vaudron, Perrine Crequit, et al.
The Prostate|July 30, 2003
C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cellsMasatoshi Eto, Jaafar Bennouna, Oriana C Hunter, et al.
Cancer Chemotherapy and Pharmacology|February 20, 2007
Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patientsMario Campone, Jeany M Rademaker-Lakhai, Jaafar Bennouna, et al.
Investigational New Drugs|May 30, 2018
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumorsSandrine Hiret, Nicolas Isambert, Carlos Gomez-Roca, et al.
Investigational New Drugs|September 25, 2014
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancerJaafar Bennouna, Marion Deslandres, Helene Senellart, et al.
Clinical Lung Cancer|January 13, 2024
Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung CancerLaurent Mathiot, Benoit Nigen, Thomas Goronflot, et al.
Cancer Research|January 19, 2012
Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivoAhmed Hamaï, Pascale Pignon, Isabelle Raimbaud, et al.
Pageof 17